Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATI-502 · 1 trial · 1 indication
Treatment emergent adverse events (TEAEs)graded on a 3 point scale of mild, moderate or severe
| Arm | Type | Description |
|---|---|---|
| ATI-502 | EXPERIMENTAL | ATI-502 topical solution applied daily for four weeks. |
| Name | Type | Description |
|---|---|---|
| ATI-502 | DRUG | Topical Solution |
Inclusion Criteria: 1. Male or non-pregnant, non-nursing female subjects ≥ 18 years old at the time of informed consent. 2. Subject must have diagnosis of AD. 3. Subject must have a diagnosis of moderate or severe AD for a period of ≥6 months prior to the first dose of study medication. 4. Body sur...
Top 20 of 26 competitors
ATI-502 is an investigational topical small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is administered as a topical solution and is in Phase 2 clinical development. It is not approved for any indication.
ATI-502 targets JAK1, a member of the Janus kinase family of kinases. JAK1 is involved in signaling pathways that drive inflammation in atopic dermatitis. By inhibiting JAK1, ATI-502 is designed to reduce inflammatory signaling in the skin.
ATI-502 is being developed by Aclaris Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker ACRS. Aclaris is responsible for the clinical development of the drug.
ATI-502 is in Phase 2 clinical development. It has completed one Phase 2 trial in atopic dermatitis. There are currently no active trials of ATI-502. The drug remains investigational and has not been approved by the FDA.
ATI-502 has been studied in one completed Phase 2 trial, NCT03585296, titled A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis. The trial enrolled 22 participants in the United States and was completed. No other trials are listed.